Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy
- Authors: Dudina K.R.1, Belyy P.A.1, Maev I.V.1, Klimova E.A.1, Shutko S.A.1, Znoyko O.O.1, Yuschuk N.D.1
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 95, No 8 (2023)
- Pages: 634-640
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/148309
- DOI: https://doi.org/10.26442/00403660.2023.08.202318
- ID: 148309
Cite item
Full Text
Abstract
Aim. To evaluate the body mass index (BMI) in patients with chronic hepatitis C (CHC) with different stages of liver fibrosis and steatosis who received effective antiviral therapy (AVT).
Materials and methods. The study included 278 CHC patients with a sustained virologic response (SVR) at the end of treatment. In addition to assessing the investigational data to determine the clinical status of the patient, we calculated BMI (following the World Health Organization guidelines) and determined the severity of liver fibrosis (F) and steatosis (S) using transient elastography. The patients were assessed at the start of antiviral therapy, after ≥6 months from the moment SVR was confirmed, and then every 12 to 24 months.
Results. By the end of the study, the mean patient age was 49 years, 53% of them were men, and 34% of the patients were obese. Excessive weight gain was registered in 17% (n=48) of the cases, with 60% newly diagnosed with Class 1 to 2 obesity. Both before the start of AVT and years after reaching SVR, the mean BMI corresponded to the reference pre-obesity values, the liver steatosis was significantly more often absent in normal BMI; on the contrary, fatty liver (predominantly S2 to S3) was registered in individuals with elevated BMI (p<0.0001). After the long-term period following a successful therapy, Stage F4 liver fibrosis patients were mainly diagnosed with obesity (80% versus 44% before AVT; p=0.0010).
Conclusion. The high proportion of patients with elevated BMI and liver steatosis seen years after a successful CHC therapy indicates a continued risk of progression of chronic liver disease. Such patients should be advised on how important it is to change their lifestyle to reduce overweight and prevent weight gain. We also need long-term assessments of how liver steatosis changes over time and what are the outcomes associated with post-SVR increase in BMI.
Full Text
##article.viewOnOriginalSite##About the authors
Kristina R. Dudina
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: dudinakr@mail.ru
ORCID iD: 0000-0002-3901-3138
д-р мед. наук, проф. каф. инфекционных болезней и эпидемиологии
Russian Federation, MoscowPetr A. Belyy
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dudinakr@mail.ru
ORCID iD: 0000-0001-5998-4874
канд. мед. наук, ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowIgor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dudinakr@mail.ru
ORCID iD: 0000-0001-6114-564X
акад. РАН, д-р мед. наук, проф., первый проректор
Russian Federation, MoscowElena A. Klimova
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dudinakr@mail.ru
ORCID iD: 0000-0003-4319-8144
д-р мед. наук, проф. каф. инфекционных болезней и эпидемиологии
Russian Federation, MoscowSvetlana A. Shutko
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dudinakr@mail.ru
ORCID iD: 0000-0003-4670-5818
канд. мед. наук, доц. каф. инфекционных болезней и эпидемиологии
Russian Federation, MoscowOlga O. Znoyko
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dudinakr@mail.ru
ORCID iD: 0000-0002-4965-596X
д-р мед. наук, проф. каф. инфекционных болезней и эпидемиологии
Russian Federation, MoscowNikolay D. Yuschuk
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dudinakr@mail.ru
ORCID iD: 0000-0002-4003-4622
акад. РАН, д-р мед. наук, проф., президент
Russian Federation, MoscowReferences
- Mazzaro C, Quartuccio L, Adinolfi LE, et al. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses. 2021;13(11):2249. doi: 10.3390/v13112249
- Mohanty A, Salameh S, Butt AA. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection. Curr HIV/AIDS Rep. 2019;16:389-94. doi: 10.1007/s11904-019-00466-1
- Chan A, Patel K, Naggie S. Genotype 3 Infection – The Last Stand of Hepatitis C Virus. Drugs. 2017;77(2):131-44. doi: 10.1007/s40265-016-0685-x
- Ando Y, Jou JH. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. Clin Liver Dis. 2021;17(1):23-8. doi: 10.1002/cld.1045
- Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94. doi: 10.1038/ajg.2017.469
- Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147-54. doi: 10.1016/S0168-8278(03)00479-3
- Жданов К.В., Карякин С.С., Козлов К.В., и др. Хронический гепатит С и неалкогольная жировая болезнь печени. Основные аспекты патогенеза. Вестник Российской Военно-медицинской академии. 2018;20(1):216-21 [Zhdanov KV, Karyakin SS, Kozlov KV, et al. Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis. Bulletin of the Russian Military Medical Academy. 2018;20(1):216-21 (in Russian)]. doi: 10.17816/brmma12326
- Chaudhari R, Sherouk F, Ashik S, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol. 2021;27(13):1267-82. doi: 10.3748/wjg.v27.i13.1267
- Lanini S, Scognamiglio P, Pisapia R, et al. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents. 2019;53:559-63. doi: 10.1016/j.ijantimicag.2018.11.024
- Информационный бюллетень ВОЗ. Ожирение и избыточный вес. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight. Ссылка активна на 02.02.2023 [World Health Organization. Fact sheets. Obesity and Overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 02.02.2023 (in Russian)].
- Schlevogt B, Boeker KHW, Mauss S, et al. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C – Results from the German Hepatitis C-Registry (DHC-R). Biomedicines. 2021;9(10):1495. doi: 10.3390/biomedicines9101495
- Do A, Esserman DA, Krishnan S, et al. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. J Gen Intern Med. 2020;35:2025-34. doi: 10.1007/s11606-020-05782-6
- El Kassas M, Alboraie M, Naguib M, et al. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol. 2019;30(8):708-13. doi: 10.5152/tjg.2019.18514
- Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739-52. doi: 10.1016/S2468-1253(20)30077-7
- Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382-90. doi: 10.1136/gutjnl-2020-322564